Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
2.030
-0.090 (-4.25%)
At close: Oct 31, 2025, 4:00 PM EST
2.160
+0.130 (6.40%)
Pre-market: Nov 3, 2025, 9:05 AM EST
Senti Biosciences Employees
Senti Biosciences had 34 employees as of December 31, 2024. The number of employees decreased by 14 or -29.17% compared to the previous year.
Employees
34
Change (1Y)
-14
Growth (1Y)
-29.17%
Revenue / Employee
n/a
Profits / Employee
-$1,789,500
Market Cap
53.11M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34 | -14 | -29.17% |
| Dec 31, 2023 | 48 | -74 | -60.66% |
| Dec 31, 2022 | 122 | 33 | 37.08% |
| Dec 31, 2021 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SNTI News
- 10 minutes ago - Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire
- 18 days ago - Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference - GlobeNewsWire
- 4 weeks ago - Senti Bio to Present at BioJapan - GlobeNewsWire
- 6 weeks ago - Senti Bio to Present at the MedInvest Biotech & Pharma Conference - GlobeNewsWire
- 2 months ago - Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 2 months ago - Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia - GlobeNewsWire
- 3 months ago - Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - GlobeNewsWire